All In Biotech

Drug Trial Radar · NCT06649344

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

A Phase III,Multicenter,Randomized,Open-label,Parallel-controlled Study Comparing the Efficacy and Safety of HRS9531 With Semaglutide in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin Monotherapy or in Combination With SGLT2 Inhibitors

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 884 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

884

Actual

Start

Oct 31, 2024

Primary completion

Jul 18, 2026

Study completion Jul 18, 2026

Sponsor

Sponsor type
Industry
First posted
Oct 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of HRS9531 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Semaglutide QW for 36 weeks and 52 weeks.

Conditions

  • Type 2 Diabetes

Interventions

  • HRS9531 InjectionDrug

    HRS9531 injected subcutaneously once weekly.

  • Semaglutide InjectionDrug

    Semaglutide injected subcutaneously once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: Week 0 to Week 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhu Xianyi Memorial Hospital,Tianjin Medical University

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.